Last Updated : Wednesday, April 1, 2020 20:20:37

Tag Archives: Zydus Cadila

CADILA HEALTH gets USFDA nod to market tablets to treat Parkinson’s disease

AHMEDABAD / MUMBAI / RAJKOT – In a regulatory update as submitted to the Indian Stock Exchanges, Ahmedabad headquartered Cadila Healthcare Ltd (Dr Pankaj Patel led Zydus Cadila Group) got USFDA (US Food and Drugs Administration) nod to market tablet to treat Parkinson’s disease or Parkinson’s like symptoms. In a company press-release titled, “Zydus receives

ZYDUS CADILA’s Diabetic treatment drug gets nod from Indian Drug Regulator

AHMEDABAD | MUMBAI | RAJKOT – In a regulatory update submitted to the Indian Stock Exchanges, Ahmedabad headquartered Dr Pankaj Patel led Zydus Group company Cadila Healthcare Ltd said of having got approval from Drug Controller General of India (DCDI) for Saroglitazar Magnesium for treatment of diabetes. To read more, please CLICK here. Long Read

CADILA inks licensing agreement to market Anemia treatment in China

AHMEDABAD | MUMBAI | RAJKOT – In a regulatory update as submitted to the Indian Stock Exchanges, Ahmedabad headquartered pharmaceutical products manufacturing company Cadila Healthcare Ltd said of having entered into licensing agreement with China Medical System Holdings for marketing anemia treatment in Greater China. The press-release titled, “Zydus and China Medical System Holdings enter

ZYDUS CADILA gets USFDA nod to market affordable anti-diabetic tablet

AHMEDABAD | MUMBAI | RAJKOT – In a regulatory update submitted to the Indian Stock Exchanges, Ahmedabad headquartered Dr Pankaj Patel owned Zydus Group’s pharma arm Cadila Healthcare Ltd said of having got nod from USFDA (US Food and Drugs Administration) to market an affordable anti-diabetic tablet Vinglyn, which is now one of the most

CADILA HEALTH (ZYDUS) gets USFDA nod to market medicine for cardiac cure & skin treatment

AHMEDABAD | MUMBAI | RAJKOT – In a regulatory update submitted to the Indian Stock Exchanges, Ahmedabad headquartered Cadila Healthcare Ltd (Dr Pankaj Patel lead Zydus Cadila Group) said of having got nod from USFDA (US Food & Drugs Administration) to market medicines to cure cardiac problems and skin-treatment. In a press-release as submitted by

Cadila gets USFDA nod to market blood-pressure, heart disease treatment drug

AHMEDABAD | MUMBAI | RAJKOT – In a press-release submitted to the Indian Stock Exchanges, Ahmedabad headquartered pharma major Cadila Healthcare Ltd (Dr. Pankaj Patel led Zydus Cadila Group) said of having got approval from US FDA (Food & Drugs Administration) to market tablets to treat blood-pressure and heart disease. The press-statement, as addressed by

Zydus announces patient enrollment in clinical trials of Saroglitazar

AHMEDABAD | MUMBAI | RAJKOT – In a regulatory filing submitted to the Indian Stock Exchanges, Ahmedabad headquartered Indian Pharma major Cadila Healthcare Ltd (Dr Pankaj Patel led Zydus Group) said of having enrolled patient(s) in evidences VII phase 2 clinical trial of Saroglitazar Magnesium. The company-statement submitted to the Indian Bourses, titled – “Zydus

USFDA classifies Zydus Cadila’s Moraiya unit vide Official Action Initiated

AHMEDABAD | MUMBAI | RAJKOT – In a regulatory updates submitted to the Indian Stock Exchanges, Ahmedabad headquartered Cadila Healthcare Ltd (Dr Pankaj Patel led Zydus Cadila Group) said of its Moraiya facility categorized vide Official Action Initiated by US FDA (Food & Drugs Administration). The statement submitted by the company to the Indian Bourses

Zydus announces completion of Phase III trial of Saroglitazar Magnesium

AHMEDABAB | MUMBAI | RAJKOT – In a press release submitted to the Indian Stock Exchanges, Ahmedabad headquartered Indian pharma major Cadila Healthcare Ltd (Dr Pankaj Patel led Zydus Cadila Group) said of having completed Phase III trials of Saroglitazar Magnesium in Type 2 Diabetes Mellitus. The press release titled, “Zydus Announces Completion of Phase

Zydus Cadila gets USFDA nod to market sedative/hypnotic (sleep disorder treatment drug)

AHMEDABAD | MUMBAI | RAJKOT – In a press release submitted to the Indian Bourses, Ahmedabad headquartered Dr. Pankaj Patel led Cadila Healthcare Ltd (Zydus Cadila Group) said of having got nod from US FDA (Food & Drugs Administration) to market drug to treat insomnia (sleep related disorders) The press release submitted by the company

Zydus Cadila completes 3-phased clinical trial enrollment for drug, to cure liver disorder

AHMEDABAD | MUMBAI | RAJKOT – In a press release submitted to the Indian Stock Exchanges, Ahmedabad headquartered Zydus Cadila Group (Cadila Healthcare Ltd) said of having completed enrollment for three phase clinical trials of drug used to treat the a progressive disease of the liver – NASH. The press release submitted to the Indian

Zydus Cadila gets USFDA nod to market high blood-pressure treatment drug

AHMEDABAD | MUMBAI | RAJKOT – In a press release submitted to the Stock Exchanges in India on Monday, Ahmedabad headquartered Zydus Cadila Group (Cadila Healthcare) said of having received the final approval from the USFDA (United States Food & Drugs Administration) to market Chlorthalidone Tablets USP (US RLD – THALITONE@),25 mg and 50 mg.

Zydus Cadila (Healthcare) gets USFDA nod to market anti-epileptic drug to prevent & control seizures

AHMEDABAD-GANDHINAGAR | MUMBAI | RAJKOT – In a press-release submitted to the Indian Bourses on Monday, Ahmedabad headquartered pharma major – Cadila Healthcare Ltd (Dr Pankaj Patel led Zydus Cadila Group) has received the tentative approval from the USFDA to market Lacosamide Tablets (US RLD – Vimpat®) in the strengths of 50 mg, 100 mg,

USFDA concludes Cadila Healthcare’s (Zydus) Pharmez facility with one observation

AHMEDABAD | MUMBAI | RAJKOT – In a regulatory filing submitted to the Indian Bourses, on Wednesday, Ahmedabad headquartered Pharma major Cadila Healthcare (Dr Pankaj Patel led Zydus Cadila Group) Ltd said of one of their units being inspected by US Food & Drugs Administration (USFDA) and the regulator has concluded the inspection with one

Cadila Healthcare (Zydus) gets USFDA nod to market tabs to cure urniery tract disorders

AHMEDABAD | MUMBAI | RAJKOT – In a regulatory filing submitted to the Indian Bourses, Ahmedabad headquartered Zydus Cadila has received the tentative approval from the USFDA to market Mirabegron Extended-Release Tablets (US RLD- Myrbetriq® Extended-Release Tablets), 25 mg and 50 mg. Mirabegron is selective beta 3-adrenoceptor agonist approved for the treatment of Overactive Bladder

Zydus Cadila gets USFDA nod, to market tablets, to treat high blood-pressure in lungs

AHMEDABAD | MUMBAI | RAJKOT – In a press-release submitted to the Indian Bourses, Ahmedabad headquartered pharma major – Cadila Healthcare Ltd (Dr Pankaj Patel owned Zydus Cadila Group) said of having received final approval from the US Food & Drugs Administration (USFDA) for Ambrisentan Tablets. The Company has received the final approval from the

Do NOT follow this link or you will be banned from the site!